Refolding Mutant p53: A Strategy to Help People with Li-Fraumeni Syndrome
Official title: Refolding Mutant p53: A Strategy for Cancer Prevention in Li-Fraumeni Syndrome
Funded at Research Inst of Fox Chase Can Ctr · NIH-11415067 · Data updated 2026-11-12
Aims to develop drugs that stabilize mutant p53 in people with Li-Fraumeni syndrome to prevent cancers before they develop.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $378,410 |
| NIH project number | 5U54CA272686-05 |
| Project ID | NIH-11415067 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with Li-Fraumeni syndrome or germline TP53 mutations who are at high risk of developing cancer might benefit in the future.
✕Less likely to help
People without Li-Fraumeni syndrome or TP53-related cancer risk are unlikely to benefit.
What this research studies
This project targets Li-Fraumeni syndrome, an inherited cancer-prone condition caused by TP53 mutations. Researchers are testing drugs that stabilize misfolded p53 so it can regain its cancer-fighting function before tumors form. The approach uses cancer cell lines and biochemical studies to understand how these drugs fix p53’s structure and activity. If successful, this could lead to prevention strategies for individuals at high risk due to TP53 mutations.
Why it matters
Potential benefit: If successful, the work could lead to a preventive therapy that reduces cancer risk for people with Li-Fraumeni syndrome.
How similar studies have gone: Previous efforts show that stabilizing p53 can influence cancer-related processes, but translating this to prevention in LFS is still under exploration.
Where this research is happening
-
Research Inst of Fox Chase Can Ctr
Philadelphia, United States Active
Researchers
- Principal investigator: Golemis, Erica a. — Research Inst of Fox Chase Can Ctr
- Study coordinator: Golemis, Erica a.
Related research
Other NIH-funded projects on the same topics.
-
Cancer screening with cell-free DNA in Li-Fraumeni Syndrome
A new, patient-friendly screening approach using blood tests to look for cancer signals in people with Li-Fraumeni Syndrome, alongside standard imaging.
-
Reversing mutations in a protein linked to cancer risk
This study is exploring a new way to help people with certain genetic mutations that affect the VHL protein, which can increase cancer risk, by developing compounds that might help the protein work better and reduce the chances of cancer.
-
Helping mutated p53 fold correctly to lower cancer risk in Li‑Fraumeni syndrome
This project tests drugs that help mutated p53 protein fold properly to lower cancer risk for people with Li‑Fraumeni syndrome.
-
Improving cancer prevention for people with Li-Fraumeni syndrome
This study is looking at how to create new medications that can help people with Li-Fraumeni syndrome by fixing a faulty protein linked to cancer, with the goal of preventing tumors from developing.
-
Using video capsules to examine patients with Lynch Syndrome
This study is testing whether video capsules can be a good alternative to regular colonoscopies for people with Lynch Syndrome to help improve cancer screening.
-
Understanding genetic causes of neuroendocrine tumors in Mexican patients
This study is trying to find out the genetic changes that cause neuroendocrine tumors in Mexican patients to help develop better treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.